BASF and Givaudan have teamed up with the Institute for In Vitro Sciences (IIVS) to validate an improved skin sensitization reactivity method to address the needs of toxicologists and regulators.
The Kinetic Direct Peptide Reactivity Assay (Kinetic DPRA) is a non-animal test developed by the duo capable of predicting allergic reactions in the skin known as sensitization. Although there are currently three international accepted non-animal sensitizer tests, the Kinetic DPRA is the only animal alternative method with the potential to predict the potency of a sensitizer.
“Being able to determine potency with minor modifications of the well-established and routinely used DPRA method was highly attractive to us,” said Robert Landsiedel, Vice President, Experimental Toxicology and Ecology, BASF. “Once validated, we hope that the Kinetic DPRA will obviate the need for further animal testing to determine potency of chemicals. We are pleased that IIVS is joining our efforts to prove the validity of the method.”
The validation project will be conducted over the course of this year and, if successful, submitted to the Organization for Economic Cooperation and Development in 2019.